Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme

2.50
Hdl Handle:
http://hdl.handle.net/11287/593859
Title:
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme
Authors:
Khan, F.; Ottensmeier, C.; Popat, S.; Dua, D.; Dorey, Nicole; Ellis, S.; Szabo, M.; Upadhyay, S.; Califano, R.; Chan, S.; Lee, L.; Ali, C. W.; Nicolson, M.; Bates, A. T.; Button, M.; Chaudhuri, A.; Mulvenna, P.; Shaw, H. M.; Danson, S. J.
Abstract:
INTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme. PATIENTS AND METHODS: Retrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy. RESULTS: Response rate and median PFS were 14.3% and 2.6months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay. CONCLUSIONS: Efficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial.
Citation:
Eur J Cancer. 2014 Jul;50(10):1717-21.
Publisher:
Elsevier
Journal:
European journal of cancer
Issue Date:
1-Jul-2014
URI:
http://hdl.handle.net/11287/593859
DOI:
10.1016/j.ejca.2014.03.001
PubMed ID:
24726055
Additional Links:
http://linkinghub.elsevier.com/retrieve/pii/S0959-8049(14)00222-6
Type:
Journal Article; Multicenter Study
Language:
eng
ISSN:
1879-0852
Appears in Collections:
2014 RD&E publications; Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorKhan, F.en
dc.contributor.authorOttensmeier, C.en
dc.contributor.authorPopat, S.en
dc.contributor.authorDua, D.en
dc.contributor.authorDorey, Nicoleen
dc.contributor.authorEllis, S.en
dc.contributor.authorSzabo, M.en
dc.contributor.authorUpadhyay, S.en
dc.contributor.authorCalifano, R.en
dc.contributor.authorChan, S.en
dc.contributor.authorLee, L.en
dc.contributor.authorAli, C. W.en
dc.contributor.authorNicolson, M.en
dc.contributor.authorBates, A. T.en
dc.contributor.authorButton, M.en
dc.contributor.authorChaudhuri, A.en
dc.contributor.authorMulvenna, P.en
dc.contributor.authorShaw, H. M.en
dc.contributor.authorDanson, S. J.en
dc.date.accessioned2016-01-19T12:35:51Zen
dc.date.available2016-01-19T12:35:51Zen
dc.date.issued2014-07-01en
dc.identifier.citationEur J Cancer. 2014 Jul;50(10):1717-21.en
dc.identifier.issn1879-0852en
dc.identifier.pmid24726055en
dc.identifier.doi10.1016/j.ejca.2014.03.001en
dc.identifier.urihttp://hdl.handle.net/11287/593859en
dc.description.abstractINTRODUCTION: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme. PATIENTS AND METHODS: Retrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy. RESULTS: Response rate and median PFS were 14.3% and 2.6months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay. CONCLUSIONS: Efficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial.en
dc.language.isoengen
dc.publisherElsevieren
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0959-8049(14)00222-6en
dc.titleAfatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programmeen
dc.typeJournal Articleen
dc.typeMulticenter Studyen
dc.identifier.journalEuropean journal of canceren

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.